MA49278A - Oligonucléotides antisens pour moduler l'expression de htra1 - Google Patents
Oligonucléotides antisens pour moduler l'expression de htra1Info
- Publication number
- MA49278A MA49278A MA049278A MA49278A MA49278A MA 49278 A MA49278 A MA 49278A MA 049278 A MA049278 A MA 049278A MA 49278 A MA49278 A MA 49278A MA 49278 A MA49278 A MA 49278A
- Authority
- MA
- Morocco
- Prior art keywords
- antisen
- htra1
- oligonucleotides
- modulate
- expression
- Prior art date
Links
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 102100021119 Serine protease HTRA1 Human genes 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21108—HtrA2 peptidase (3.4.21.108)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173964 | 2017-06-01 | ||
| EP17209407 | 2017-12-21 | ||
| EP17209535 | 2017-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49278A true MA49278A (fr) | 2020-04-08 |
Family
ID=62245334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049278A MA49278A (fr) | 2017-06-01 | 2018-05-30 | Oligonucléotides antisens pour moduler l'expression de htra1 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190055564A1 (enExample) |
| EP (1) | EP3630976A1 (enExample) |
| JP (1) | JP7169995B2 (enExample) |
| KR (1) | KR20200015608A (enExample) |
| CN (1) | CN110691849A (enExample) |
| AU (1) | AU2018277219A1 (enExample) |
| BR (1) | BR112019025290A2 (enExample) |
| CA (1) | CA3062590A1 (enExample) |
| CL (1) | CL2019003337A1 (enExample) |
| CO (1) | CO2019013317A2 (enExample) |
| CR (1) | CR20190543A (enExample) |
| IL (1) | IL271039A (enExample) |
| MA (1) | MA49278A (enExample) |
| MX (1) | MX2019014187A (enExample) |
| PE (1) | PE20191845A1 (enExample) |
| PH (1) | PH12019502636A1 (enExample) |
| RU (1) | RU2019143004A (enExample) |
| TW (1) | TW201907008A (enExample) |
| WO (1) | WO2018220034A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019101298A (ru) | 2016-07-01 | 2020-08-03 | Ф. Хоффманн-Ля Рош Аг | Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| CN116507741A (zh) * | 2020-08-20 | 2023-07-28 | 基因组评论股份有限公司 | 年龄相关性黄斑变性诊断用生物标记物及其用途 |
| JPWO2022092326A1 (enExample) * | 2020-10-30 | 2022-05-05 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| AU5290499A (en) * | 1998-08-03 | 2000-02-28 | Novartis Ag | Human htra serine protease |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| EP1888083B1 (en) * | 2005-05-24 | 2011-12-28 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to lmw-ptpase |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| MX2009000909A (es) | 2006-07-26 | 2009-02-04 | Univ Yale | Diagnostico y tratamiento de degeneracion macular relacionada con la edad. |
| US20100166743A1 (en) * | 2006-10-06 | 2010-07-01 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| TW200911290A (en) | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009059317A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| FR2965278B1 (fr) * | 2010-09-23 | 2014-10-10 | Univ Caen Basse Normandie | Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations |
| EP2753631A1 (en) | 2011-09-07 | 2014-07-16 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013173637A1 (en) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2018087200A1 (en) * | 2016-11-11 | 2018-05-17 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
-
2018
- 2018-05-29 US US15/991,326 patent/US20190055564A1/en not_active Abandoned
- 2018-05-30 CR CR20190543A patent/CR20190543A/es unknown
- 2018-05-30 CN CN201880036053.5A patent/CN110691849A/zh active Pending
- 2018-05-30 AU AU2018277219A patent/AU2018277219A1/en not_active Abandoned
- 2018-05-30 PE PE2019002473A patent/PE20191845A1/es unknown
- 2018-05-30 MX MX2019014187A patent/MX2019014187A/es unknown
- 2018-05-30 RU RU2019143004A patent/RU2019143004A/ru unknown
- 2018-05-30 JP JP2019566236A patent/JP7169995B2/ja not_active Expired - Fee Related
- 2018-05-30 KR KR1020197038723A patent/KR20200015608A/ko not_active Withdrawn
- 2018-05-30 EP EP18727310.7A patent/EP3630976A1/en not_active Withdrawn
- 2018-05-30 CA CA3062590A patent/CA3062590A1/en not_active Abandoned
- 2018-05-30 BR BR112019025290-8A patent/BR112019025290A2/pt not_active Application Discontinuation
- 2018-05-30 WO PCT/EP2018/064221 patent/WO2018220034A1/en not_active Ceased
- 2018-05-30 MA MA049278A patent/MA49278A/fr unknown
- 2018-05-31 TW TW107118609A patent/TW201907008A/zh unknown
-
2019
- 2019-10-28 US US16/665,317 patent/US20200157546A1/en not_active Abandoned
- 2019-11-20 CL CL2019003337A patent/CL2019003337A1/es unknown
- 2019-11-22 PH PH12019502636A patent/PH12019502636A1/en unknown
- 2019-11-27 CO CONC2019/0013317A patent/CO2019013317A2/es unknown
- 2019-11-28 IL IL271039A patent/IL271039A/en unknown
-
2021
- 2021-08-17 US US17/404,989 patent/US20220042022A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR20190543A (es) | 2020-02-10 |
| JP7169995B2 (ja) | 2022-11-11 |
| CO2019013317A2 (es) | 2020-01-17 |
| CN110691849A (zh) | 2020-01-14 |
| PE20191845A1 (es) | 2019-12-31 |
| IL271039A (en) | 2020-01-30 |
| JP2020521491A (ja) | 2020-07-27 |
| RU2019143004A (ru) | 2021-07-09 |
| US20200157546A1 (en) | 2020-05-21 |
| PH12019502636A1 (en) | 2020-06-08 |
| CA3062590A1 (en) | 2018-12-06 |
| WO2018220034A1 (en) | 2018-12-06 |
| EP3630976A1 (en) | 2020-04-08 |
| US20190055564A1 (en) | 2019-02-21 |
| MX2019014187A (es) | 2020-01-27 |
| US20220042022A1 (en) | 2022-02-10 |
| CL2019003337A1 (es) | 2020-05-15 |
| TW201907008A (zh) | 2019-02-16 |
| BR112019025290A2 (pt) | 2020-06-23 |
| KR20200015608A (ko) | 2020-02-12 |
| AU2018277219A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| EP3607023C0 (en) | MICELLAR SOLUTIONS TO TREAT A HYDROCARBON FORMATION | |
| EP3334499A4 (en) | BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES | |
| EP3679141C0 (en) | METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| PT3506909T (pt) | Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos | |
| EP3526328A4 (en) | COMBINATION THERAPY FOR C3 INHIBITION | |
| EP3353328A4 (en) | MODULATORS OF KRAS EXPRESSION | |
| EP3402549A4 (en) | MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF | |
| EP3431075A4 (en) | EDARAVONDARREICHUNGSFORM | |
| IL290449A (en) | Antibody-mediated neutralization of chikungunya virus | |
| EP3325963A4 (en) | INCREASE OF BLOOD CELL ESTIMATION | |
| EP3853365A4 (en) | MODULATORS OF PNPLA3 EXPRESSION | |
| MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
| IL269735A (en) | Antisense oligonucleotides for the treatment of stargardt disease | |
| EP3634426A4 (en) | COMPOSITIONS FOR TREATMENT OF FIBROSE | |
| EP3470052A4 (en) | EYE COSMETIC COMPOSITION | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| MA51795A (fr) | Oligonucléotides pour moduler l'expression de tmem106b | |
| EP3397288A4 (en) | PROCESS FOR REDUCING ATAXIN-2 EXPRESSION | |
| EP3541379A4 (en) | COMPOSITIONS FOR THE TREATMENT OF HYPERTONIA | |
| EP3403655A4 (en) | COMPOSITION TO INCREASE EXPRESSION OF PGC-1 | |
| MA53474A (fr) | Distribution de lingettes | |
| EP3424868A4 (en) | EXPANSION / CONTRACTION MECHANISM | |
| EP3733177A4 (en) | COMPOSITION FOR CORNEAL PROTECTION |